UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002001 |
|---|---|
| Receipt number | R000002437 |
| Scientific Title | Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors. |
| Date of disclosure of the study information | 2009/05/24 |
| Last modified on | 2020/06/01 11:13:52 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.
Acronym
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.
Scientific Title
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.
Scientific Title:Acronym
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.
Region
| Japan |
Condition
Condition
Malignant solid tumors,
Malignant lymphoma,
Multiple Myeloma, Acute leukemia
Classification by specialty
| Medicine in general | Hematology and clinical oncology | Surgery in general |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
Safety
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Phase I,II
Assessment
Primary outcomes
1. Safety
Evaluation by NCI-CTCAE ver 3.0
2. Efficacy
Clinical response rate
Disease control rate
Key secondary outcomes
1. QOL outcomes
2. Immune responses to WT1
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine | Vaccine |
Interventions/Control_1
The patient is intradermally injected with 3 mg of the HLA-A*2402-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMNL) emulsified with Montanide ISA51 adjuvant. The WT1 vaccination was scheduled to be performed 12 times at weekly intervals. The safety and efficacy are evaluated by the NCI-CTC and RECIST criteria from 1 to 3 weeks after 12th WT1 vaccination .
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 16 | years-old | <= |
Age-upper limit
| 79 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1. Diagnosed as malignant solid tumors, malignant lymphoma, mutiple myeloma or acute leukemia.
2. Informed about his diagnosis
3. Not expected to make any further efficacy by standard treatment
4. WT1 expression in malignant cells
5. HLA-A*2402 positive
6. Having evaluable diaseas
7. No chemotherapy/radiation has been performed within 4 weeks and no hormone/BRM therapy has been performed within 3 weeks before the start of vaccination.
8. There is not uncontrolable brain metastasis.
9. Performance status (ECOG) 0-1
10. Meet the following criteria for organ functions
1)Neutrophil more than 1,000/microliter, Platelet more than 75,000/microliter, Hemoglobin more than 8g/dl
2) Serum creatinine less than 2.0 mg/dL
3) Serum bilirubin less than 1.5 folds of the upper normal limit
4) Serum AST/GOT less than 3 folds of the upper normal limit
5) Serum Albumin more than 2.5g/dl
6) Arterial oxygen saturation more than 94% in room air
11. Pleural effusion, ascites and pericardial effusion are not detected or
controlled.
12 Survival period is expected more than 3 months
13. Informed consent has been obtained
Key exclusion criteria
1. There is deep-seated active infection.
2,3 There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis.Patients who have complications that are considered inappropriate for the trial.
4. Dependent on total parenteral nutrition(TPN)
5. There is expanded liver metastasis.
6. There are other malignancies.
7. There are hematopoietic stem cell disorders such as myelodisplastic syndorome(MDS) and myeloproliferative disorders (MPD).
8. Post allogeneic hematopoietic stem cell transplantation
9. Pregnant or lactating woman
10. There is severe psychiatric disorder.
11. Responsible doctors judged the patient inappropriate for the trial
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | Haruo |
| Middle name | |
| Last name | Sugiyama |
Organization
Osaka University Graduate School of Medicine
Division name
Department of Clinical Laboratory Science
Zip code
565-0871
Address
1-7, Yamada-oka, Suita City, Osaka , Japan
TEL
06-6879-2593
sugiyama@sahs.med.osaka-u.ac.jp
Public contact
Name of contact person
| 1st name | Oka |
| Middle name | |
| Last name | Yoshihiro |
Organization
Osaka University Graduate School of Medicine
Division name
Department of Cancer Immunotherapy
Zip code
565-9871
Address
2-2, Yamada-oka, Suita City, Osaka, Japan
TEL
06-6879-3676
Homepage URL
http://sahswww.med.osaka-u.ac.jp/~hmtonc/vaccine/index.htm
yoshi@cit.med.osaka-u.ac.jp
Sponsor or person
Institute
Department of Cancer immunotherapy, Osaka University Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Ministry of Education, Culture, Sports, Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Academic Clinical Research Center of Osaka University Hospital
Address
2-2 yamada-0ka, Suita Cit, Osaka
Tel
0662108290
acr-jim@dmi.med.osaka-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 05 | Month | 24 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2003 | Year | 10 | Month | 10 | Day |
Date of IRB
Anticipated trial start date
| 2003 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2009 | Year | 05 | Month | 24 | Day |
Last modified on
| 2020 | Year | 06 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002437
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
